Trial Parameters
Condition Metastasis
Sponsor Da Fu
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2016-01
Completion 2026-12
Interventions
normal colorectal tissues
Brief Summary
The investigators will perform integrative analysis of CRC liver metastasis
Eligibility Criteria
Inclusion Criteria: * Age ≤ 75 years with histologically proven CRC * No severe major organ dysfunction * WHO performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * World Health Organization (WHO) performance status of \>1 * Prior cancer chemotherapy
Related Trials
NCT02917707
Integrative Analysis of CRC Liver Metastasis
View Trial →
NCT06567353
A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
View Trial →
NCT06362369
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherap
View Trial →